IL17A and Cowden syndrome 1: Altogether, it is possible to suggest that increased levels of IL-10 during the early phase of CS therapy arise from pro-inflammatory cells expressing cytokines such as IL-17A, leading to an increase in anti-inflammatory with little to no difference in the expression of pro-inflammatory markers.